Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dimerix Limited ( (AU:DXB) ) has provided an update.
Dimerix Limited has announced the issuance of 20,250 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB as of April 28, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor relations positively.
More about Dimerix Limited
Dimerix Limited operates within the biotechnology industry, focusing on the development of innovative pharmaceutical products. The company is primarily engaged in creating therapies for unmet medical needs, particularly in the field of kidney disease and other inflammatory conditions.
YTD Price Performance: 33.82%
Average Trading Volume: 1,502,800
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$254.5M
Learn more about DXB stock on TipRanks’ Stock Analysis page.